Cotadutide
Dual GLP-1 and glucagon receptor agonist in clinical development for obesity and NASH. Studied for metabolic benefits beyond GLP-1 alone through glucagon-mediated energy expenditure.
0 anonymous reports
Also known as:
medi0382glp-1 glucagon dual
browse topics:
community guides:
No reports found.
Community Q&A
- What is cotadutide used for?
- Community accounts describe cotadutide in the context of next-generation GLP-1 alternatives — specifically its dual mechanism hitting GLP-1 for appetite and glucagon for energy expenditure. Accounts from early adopters who sourced it describe it as producing weight loss with a different side effect profile than pure GLP-1 agents. NASH treatment context also appears in confessions from users with liver-related metabolic concerns.
- How does cotadutide compare to tirzepatide?
- Community accounts that compare describe both as dual-mechanism compounds but with different second targets: tirzepatide adds GIP, cotadutide adds glucagon. The glucagon component in cotadutide accounts is associated with faster metabolic rate elevation. Side effect comparisons are limited — cotadutide has a smaller community footprint than tirzepatide, making head-to-head accounts rare.